Loading...
•
Mar 31, 2021
Immunome Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Key Takeaways
Immunome reported its Q1 2021 financial results, highlighting progress in its product pipeline, including IMM-BCP-01 and IMM-ONC-01. The company also appointed Dennis Giesing, Ph.D. as Chief Development Officer and Corleen Roche as Chief Financial Officer and raised $27 million in gross proceeds in a private placement.
IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing
IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies
Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer
Raised $27 million in gross proceeds in a private placement
Immunome
Immunome
Forward Guidance
This press release includes certain forward-looking statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings.